Clinical trials

A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)

A Single Arm Trial of External Beam Radiation Therapy (EBRT) in Combination with 177Lu-DOTA-TLX591 Theranostic in Patients with Biochemically Recurrent, Oligometastatic, Prostate Specific Membrane Antigen- Expressing Prostate Cancer

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)

A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)

A First-in-human, Phase I Trial of study drug, a Bispecific Antibody Targeting PD-L1 and OX-40 in Patients with Advanced or metastatic Solid Tumours

To evaluate the efficacy and safety of a new valve in patients with severe, symptomatic aortic stenosis.

To evaluate a new device in patients with prior acute coronary syndrome.

To evaluate the efficacy and safety on a new drug in participants with Mixed Dyslipidaemia.

A multi-center open-label, phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ICP-192 in patients with advanced solid tumours and FGFR gene alterations

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer detected by PSMA.

Can Coronary Artery Calcium Score identified on thoracic planning ct scans be used and actioned to identify patients at high risk of cardiac events: a feasibility study in patients with cancer undergoing radiotherapy (ro-cardiac)

A Phase 3 Multicenter, Randomized, Open-label,Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation

A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumours With KRAS p.G12C Mutation

To evaluate the impact of a new medication on participants who have established cardiovascular disease and who have had a major adverse cardiovascular event.

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Pro

An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)

A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation.

Efficacy of Personalised Irradiation with Rhenium-SCT Skin Cancer Therapy (SCT) for the treatment of non-melanoma skin cancer; a phase IV, multi-centre, international, open label, single arm study

A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH.

The aim of this study is to assess the efficacy of delivering chemotherapy treatment through the arteries directly to the liver, bypassing the main blood supply throughout the body.

A Multicountry, Multicentre, Noninterventional Retrospective Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer.

A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAFV600E-MUTANT, MSI-H/DMMR METASTATIC COL

Safety, tolerability, biodistribution, dosimetry and efficacy study of 177Lu-DOTA-TLX591-CHO with best standard of care in patients with PSMA expressing metastatic castration-resistant prostate cancer.

To evaluate a new medication for the treatment of patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM).

To evaluate a new mitral valve replacement in patients who moderate-severe or severe mitral regurgitation at a high surgical risk.

To evaluate the efficacy and safety of a new drug on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥40% (LVEF ≥40%).

Clinical trial of patients with AF and their acceptability of MultiPulse Therapy (low voltage energy used to terminate tachyarrhythmias) prior to their clinically indicated electrophysiology procedure

To evaluate if treatment with a new drug reduces the risk cardiovascular disease in patients with established cardiovascular disease, chronic kidney disease and inflammation.

Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antagonist Oral Anticoagulants.

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy.

Clinical trial of patients with AF and their acceptability of MultiPulse Therapy (low voltage energy used to terminate tachyarrhythmias) prior to their clinically indicated electrophysiology procedure

To collect data and evaluate the safety of Cardiac Resynchronisation Therapy (CRT) by utilising new techniques and investigational systems for patients in heart failure.

The purpose of this study is to see if a new drug, darolutamide, combined with the current best treatments, can improve outcomes for people with prostate cancer.

The aim of this study is to compare treatment informed by ctDNA results to standard care in patients with stage III colon cancer.

This study will consist of four groups with the initial three groups undergoing dose escalation and the fourth group will be to confirm the optimal dose and imaging conditions.

The purpose of the study is to compare progression-free survival between Arm A and Arm B as assessed by investigators according to Response Evaluation Criteria in Solid Tumors Version 1.1.

The NINJA clinical trial aims to compare two emerging schedules of radiotherapy in the treatment of prostate cancer.

This study will assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.

This is a prospective, multicentre randomised, phase II clinical trial, with randomisation 2:1 by minimisation and stratification by tumour stage, planned chemotherapy and institution.

A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC.

Adding mitomycin C to BCF as adjuvant intravesical therapy for high-risk, non muscle invasive bladder cancer, a randomised phase 3 trial.

This study is designed to test the safety and potential benefit of adding an existing drug used for bone protection (denosumab) to a new immune stimulating drug (pembrolizumab).

The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with MPM.

The purpose of this trial is to see if a reduced radiotherapy can deliver equivalent treatment response to full dose radiotherapy for patients with skin cancer.

This study aims to clinically validate use of the Baker Skin Field Cancerisation Tool (BSFCT) in people attending St Vincent’s Hospital Melbourne dermatology clinic.

Phase II targeted therapy or immunotherapy guided by genomic profiling versus platinum based chemotherapy (3C) (after receiving three cycles of platinum based chemotherapy).

Assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC).

Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR).

This study will examine the efficacy and safety of trastuzumab deruxtecan compared with trastuzumab emtansine in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma.

A comparison of two routinely used skin treatments for women with breast cancer undergoing radiation therapy.

The hypothesis of study is addition of apalutamide to RT+ LHRHa provides superior efficacy in terms of PSMA-PET metastatic progression-free survival-ppMPFS.

A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC).

Evaluation of Oedema and lymphatic function following volumetric modulated arc therapy for non-melanoma extensive skin field cancerisation of the lower limbs.

The purpose of this study is to determine the effect of androgen deprivation therapy, a treatment commonly prescribed in prostate cancer patients, on the effectiveness of medical imaging techniques.

A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High-Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial.

A Long-Term, Prospective and Retrospective, Observational Registry Assessing Technical Data and Clinical Outcomes Following Treatment with MR-Linac.

The purpose of this study is to assess the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in participants with untreated, confirmed Prostate Cancer.

Investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.

GenesisCare is recruiting patients with Dupuytren’s Disease for a research study called ‘DEPART’.

To evaluate a new valve, the Portico™ NG Transcatheter Aortic Heart Valve, in patients who have symptomatic, severe aortic stenosis and are determined to be at high or extreme surgical risk.

To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy.

To evaluate a new valve in patients with moderate-severe or severe mitral regurgitation and at high surgical risk.

To collect data to evaluate specified outcomes for patients undergoing radiotherapy for skin cancer and inflammatory skin conditions.

A unique opportunity to improve personalised use of radiation therapy in patients with early breast cancer according to their individual risks of local recurrence.